Drugs / AG 6013736
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00176748 | Jul 2005 → Aug 2006 | thyroid cancer | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AG 6013736 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00176748 ↗ |
| Known as | AG-013736 | “called AG-013736” NCT00176748 ↗ |
| Action | Inhibit | “inhibit the VEGF receptor tyrosine kinase (VEGFR TK) signaling pathway” NCT00176748 ↗ |
| Route | Oral | “5 mg po bid” NCT00176748 ↗ |